The Lancet Oncology: Proton beam therapy offers potential to treat childhood brain cancer with fewer severe side effects than conventional radiotherapy
(The Lancet) Proton beam therapy -- a more precise form of radiotherapy -- to treat the childhood brain cancer medulloblastoma appears to be as safe as conventional radiotherapy with similar survival rates, according to new research published in The Lancet Oncology journal today. Importantly, the findings suggest that proton radiotherapy may not be as toxic to the rest of a child's body as conventional radiotherapy. The study was led by Dr. Torunn Yock, Massachusetts General Hospital, Proton Center, Boston, Mass., USA, and colleagues. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 29, 2016 Category: Global & Universal Source Type: news
Proton Therapy Controls Common Pediatric Brain Tumor with Fewer Long-Term Side Effects (Massachusetts General Hospital Cancer Center)
The use of proton radiotherapy to treat the most common malignant brain tumor in children is as effective as standard photon (x-ray) radiation therapy while causing fewer long-term side effects such as hearing loss and cognitive disorders, according to a study receiving online publication in Lancet Oncology. The paper from a team led by Massachusetts General Hospital (MGH) investigators describes patient outcomes an average of seven years after proton therapy for medulloblastoma, a fast-growing ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 29, 2016 Category: Cancer & Oncology Source Type: news
Researchers mine the epigenome to identify likely origins of childhood brain tumor subtype
(St. Jude Children's Research Hospital) An international research team led by a St. Jude Children's Research Hospital scientist mined the epigenome to discover the likely cell of origin for Group 4 medulloblastoma, a key step in developing targeted therapies (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 27, 2016 Category: Biology Source Type: news
Scientists identify protein interaction that defines an aggressive brain tumor subtype
Researchers show how the interaction of two proteins leads to medulloblastoma subtype with the worst prognosis. They also report that they have discovered a possible treatment strategy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 11, 2016 Category: Science Source Type: news
Scientists identify protein interaction that defines an aggressive brain tumor subtype
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital and University of Würzburg show how the interaction of two proteins leads to medulloblastoma subtype with the worst prognosis; scientists also discover possible treatment strategy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2016 Category: Global & Universal Source Type: news
[Editors' Choice] Channeling brain cancer
Drug development based on the antipsychotic drug thioridazine may lead to treatments for metastatic medulloblastoma without compromising quality of life. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - September 1, 2015 Category: Science Authors: Nancy Gough (mailto:ngough at aaas.org) Source Type: news
Father with brain tumour is given just weeks to live
Alex Lewis Mayhew, 40, of Ibstock, Leicestershire, has been diagnosed with medulloblastoma, a brain tumour commonly found in children and has been told he will not live longer than a month. (Source: the Mail online | Health)
Source: the Mail online | Health - August 24, 2015 Category: Consumer Health News Source Type: news
Pediatric brain tumors can be classified noninvasively at diagnosis
Medulloblastoma, the most commonly occurring malignant brain tumor in children, can be classified into four subgroups -- each with a different risk profile requiring subgroup-specific therapy. Investigators have now discovered that these subgroups can be determined non-invasively, using magnetic resonance spectroscopy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 7, 2015 Category: Science Source Type: news
Pediatric brain tumors can be classified noninvasively at diagnosis
(Children's Hospital Los Angeles) Medulloblastoma, the most commonly occurring malignant brain tumor in children, can be classified into four subgroups -- each with a different risk profile requiring subgroup-specific therapy. Investigators at Children's Hospital Los Angeles have now discovered that these subgroups can be determined non-invasively, using magnetic resonance spectroscopy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 7, 2015 Category: Global & Universal Source Type: news
Targeted therapy shows effectiveness against a subtype of the brain tumor medulloblastoma
A subset of medulloblastoma tumors briefly stopped growing or disappeared entirely during treatment with vismodegib, researchers report after a trial with both adults and children. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 30, 2015 Category: Science Source Type: news
Targeted therapy shows effectiveness against a subtype of the brain tumor medulloblastoma
(St. Jude Children's Research Hospital) A subset of medulloblastoma tumors briefly stopped growing or disappeared entirely during treatment with vismodegib; St. Jude Children's Hospital led the Pediatric Brain Tumor Consortium trials in children and adults. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 29, 2015 Category: Global & Universal Source Type: news
Targeted Therapy Shows Effectiveness against a Subtype of the Brain Tumor Medulloblastoma
A targeted therapy already used to treat advanced skin cancer is also effective against the most common subtype of the brain tumor medulloblastoma in adults and should be considered for treatment of newly diagnosed patients, according to research led by St. Jude Children's Research Hospital.
St. Jude Children's Research Hospital/University of Tennessee Health Science Center is one of the 26 NCCN Member Institutions.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - July 29, 2015 Category: Cancer & Oncology Source Type: news
New drug for neuroblastoma shows promise in phase I study
(Spectrum Health) Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, M.D., and the Neuroblastoma and Medulloblastoma Translational Research Consortium, DFMO, an investigational agent, showed minimal side effects with long-term survival of three patients. This is the first clinical study of an oral dosing form of DFMO in any pediatric population. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 1, 2015 Category: Biology Source Type: news
TGen, Dell expand pediatric cancer fight to Europe and Middle East
(The Translational Genomics Research Institute) Dell today announced its extended partnership with the Translational Genomics Research Institute (TGen) to help clinical researchers and doctors globally expand the reach and impact of the world's first FDA-approved precision medicine trial for pediatric cancer. The renewed commitment includes an additional $3 million Dell grant to support continued collaboration with TGen and support the Neuroblastoma and Medulloblastoma Translational Research Consortium's expanded pediatric cancer clinical trials in EMEA, starting with sites in France and Lebanon. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 11, 2015 Category: Cancer & Oncology Source Type: news
Tracking defects caused by brain tumor mutation yields insight to advance targeted therapy
Scientists have gained ground toward developing more targeted therapies for the most common childhood brain tumor. The findings involve the DDX3X gene. In 2012, other work highlighted DDX3X as a promising focus for efforts to develop targeted therapies against medulloblastoma. Such treatments target the genetic mistakes that give rise to the brain tumor’s four subtypes. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 8, 2015 Category: Science Source Type: news
